Side-by-side · Research reference

GHRP-2vsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED15/42 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

GHRP-2

Hexapeptide GHRP · Phase 2 (clinical diagnostic)

100–300 mcgPer doseBowers 1990

Phase 2Evidence levelBowers 1990 Sigalos 2018

~30 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

GHRP-2

Testagen

Primary target

Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990

Testicular tissue; proposed nuclear DNA interaction

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

Yes, with somatostatin feedback active

Unknown — no HPG axis data

Origin

Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

GHRP-2

Testagen

Standard dose

100–300 mcg per injectionBowers 1990

—

Frequency

1–3× per day

Once daily or alternate days

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 2 + clinical diagnostic useBowers 1990

Animal mechanistic / in vitro onlyFedoreyeva 2011

Duration

8–12 weeks on / 4 off (anecdotal)

—

Reconstitution

Bacteriostatic water

Sterile water or bacteriostatic saline

Timing

Pre-sleep + fasted preferred

—

Half-life

~30 minMalagón 1999

Unknown — likely minutes (short peptide)

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

04Side Effects & Safety

Parameter

GHRP-2

Testagen

Cortisol elevation

Mild but measurableBowers 1990

—

Prolactin elevation

Mild but measurable

—

Hunger

Strong appetite increase

—

Injection site reaction

Mild erythema

—

IGF-1 elevation

Strong; monitor with chronic high-dose use

—

Cancer risk

Contraindicated in active malignancy

—

Pregnancy / OB

Avoid

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

GHRP-2

·Active malignancy
·Pregnancy / breastfeeding

Testagen

·Active testicular malignancy

Relative Contraindications

GHRP-2

·Untreated diabetes

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

GHRP-2

Testagen

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Injection site

SQ — abdomen or thigh. Rotate sites.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Timing

Pre-sleep + fasted preferred.

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Needle

29–31G, 4–8 mm insulin syringe.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

06Stack Synergy

GHRP-2

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

GHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.

GHRP-2: 100–200 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: High-amplitude GH pulse, body composition

Bowers 1990 Teichman 2006

Testagen

— no documented stacks